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Abstract  
 Background: proton pump inhibitors are widely used worldwide and 
studies have demonstrated that the use of  PPIs to be associated with various 
diseases such as several types of infection. 
Study objectives: to explore the effect of using PPIs on patients through 
studying some inflammatory biomarkers including WBC, neutrophil count, 
ESR, CRP, and IL-6.  
Methods and subjects: a retrospective study design was followed to collect 
data from study participants. The study included 62 patients receiving PPIs 
and 60 persons without being prescribed for PPIs. A working sheet was 
created for each patient and included the following information: age, WBC, 
neutrophil count, ESR, CRP, and IL-6. Data analysis was carried out using 
SPSS version 20. The relationship between variables was tested using 
independent T test. Significance was considered at alpha level < 0.05. 
Study findings: age was not varied significantly between study group and 
control group. All inflammatory biomarkers under study were significantly 
elevated in study group compared with control group.  
Conclusions: the findings of the present study showed that the use of PPIs 
was associated significantly with increased inflammatory biomarkers. We 
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think that health settings should pay much attention to the role of 
pharmacists and pharmacy doctors to increase the awareness about the use of 
PPIs.  
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Introduction  
 Proton pump inhibitors (PPIs) are prescribed to prevent the 
production of  gastric parietal cell acid through the irreversible inhibition of 
the luminal H+/K+ adenylpyrophosphatase (ATPase) (Lindberg et al., 2003).  
Reviewing literature showed the use of PPIs in various inflammatory 
conditions such as  upper gastrointestinal tract infection, erosive esophagitis, 
gastric and duodenal ulcers (Vandenplas et al., 2009; Koletzko et al., 2011; 
Dellon et al., 2013).    
 PPIs have been reported to be highly prescribed due to their 
effectiveness and safety. Among PPIs is omeprazole which is one of the 
most popular drugs worldwide. It has been assumed that omeprazole is a 
potential drug for treating several diseases (García-Torres et al., 2016).  
 The study of García-Torres et al (2016) has shown that omeprazole 
has cytotoxic effects in Giardia and it can inactivate giardial triosephosphate 
isomerase (GlTIM). The researchers thought that PPIs act through modifying 
the Cys 222 residue. Furthermore, significant changes on structural level, 
thermal stability of inactivated- GlTIM was observed. 
 Yu et al (2015) conducted a study to  assess the association between 
PPI use and spontaneous bacterial peritonitis (SBP) incidence and mortality 
using case control and cohort studies. Researchers analyzed 10 case–control 
and six cohort studies which included 8145 patients. Findings indicated that 
PPI use was associated with SBP (OR = 2.11, 95% CI: 1.46–3.06). 
Furthermore, no association was observed between PPI therapy and mortality 
during hospitalization or within 30days after SBP.  
 Landray et al (1998) reported that the use of omeprazole induced 
inflammatory reactions which were reflected through increased levels of 
erythrocyte sedimentation rated (ESR).  
 Simpson et al (2006) conducted a study to study the clinical 
parameters of 15 patients who had acute interstitial nephritis (AIN) and acute 
renal failure due to the prescription of PPI. Study findings showed that both 
ESR and CRP were increased during time of diagnosis. The mean of ESR 
was 85 mm/h, and that of CRP was 81 mg/L. 
 Sanduleanu et al (2003) conducted a study to examine hypothesis that 
serum cytokines may offer additional data to gastrin and pepsinogens in 
screening for atrophic body gastritis (ABG). Study findings showed that 
patients with ABG had significantly higher serum gastrin (P < 0.01) than 
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those without ABG. furthermore, study findings showed that the levels of 
serum  IL-6  were significantly higher in the subjects with ABG than in those 
without ABG (P < 0.0001).  
 Gouraud et al (2010) conducted a study taking into account several 
considerations among which are PPIs are widely used with efficacy and well 
tolerance.  Another consideration was that neutropenia and agranulocytosis 
are considered rarely adverse conditions to occur in association with 
treatment by PPI. According to authors, the use of omeprazole has been 
involved in previous works involving isolated neutropenia. The authors 
described a case of omeprazole induced neutropenia with further recurrence 
upon pantoprazole treatment. The treatment with omeprazole increased both 
white blood count and neutropenia. When the treatment with  omeprazole 
discontinued, white blood count and neutrophil count returned to normal 
range.   
 
Study objectives  
 The main objective of the present study was to explore the effect of 
using PPIs on patients through studying some inflammatory biomarkers 
including WBC, neutrophil count, ESR, CRP, and IL-6.  
 
Methods and subjects  
Study design and setting 
 A retrospective study design was followed to collect data from study 
participants. The study was conducted at Royal Medical Services. 
 
Study sample 
 Study sample included 62 patients with prescribed PPIs and 60 
subjects without PPIs as a control group. 
 
Study procedure 
 An ethical approval was obtained from the IRB committee from 
Jordanian Royal Medical Services. A working sheet was prepared for each 
patient which included the required information about patients including age, 
white blood cell count (WBC). Interleukin- 6 (IL-6), neutrophil count, 
erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Data 
was filled for each participant in an excel sheet to collect the raw data for 
each patient. In a further step, data was analyzed using SPSS version 20. 
Independent T test was used to investigate the relationship between study 
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Results 
 As seen in table 1, the mean age of patients in study group was 
55.34+ 13.54years, and this was less than that of control group 57.06 + 10.27 
years. No significant variations were observed between study and control 
groups (p=0.516).  
 Study findings showed that all inflammatory markers under study 
were significantly higher in study group compared with control group. WBC 
mean in study group was 8.23+1.52 X103 which was significantly higher 
than that of control group 6.34+ 1.58 X103 (p=0.001). The mean level of IL-
6 was  19956.86+2620.24 and this was significantly (p=0.000) higher than 
that of control group  13318.85+8297.30. The neutrophil count in study 
group (8.13+1.66) was significantly higher (p=0.000) than that of control 
group (4.14+1.77). The results also indicated that the mean level of ESR in 
study group was 38.5+ 21.7mm/hr, and this was higher than that of control 
group 20.1+ 10.76mm/hr. This variation was statistically significant 
(p=0.000). The mean level of CRP in study group was 36.80+ 26.80, while 
in control group, it was 2.40+2.60. The variation was statistically significant 
(p=0.000). 
Tale 1: General characteristics of participants 
Variable  Study group Control group P value 
Mean SD Mean SD 
Age  55.34  13.54 57.06 10.27 0.516 
WBC 8.23 1.52 6.34 1.58 0.001 
IL-6 19956.86 2620.24 13318.85 8297.30 0.000 
Neutrophils  8.13 1.66 4.14 1.77 0.000 
ESR 38.5 21.7 20.1 10.76 0.000 
CRP 36.80 26.8 2.40 2.60 0.000 
 
Discussion  
 The present study was conducted in view of the facts that PPIs are 
widely used in the local and global level. The purpose of this study was to 
explore the effect of PPIs on patients.  
 We studied the effects of PPIs on several inflammatory biomarkers 
including WBC, neutrophil count, ESR, and CRP. 
 We showed that the mean of WBC and neutrophil count in study 
groups were significantly higher than that in control group (p=0.000). Our 
findings confirmed the findings of other studies such as the study of Gouraud 
et al (2010) who reported increased WBC and neutrophil levels to be 
associated with PPIs including the uses of omeprazole treatment. 
 The study findings showed that the levels of IL-6 was significantly 
increased in study group compared with control group (p=0.000). Our 
findings agree with other reported studies including the study of Sanduleanu 
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et al (2003) who reported that all cytokines including IL-6 were significantly 
elevated in patients with ABG compared with persons without ABG. 
 Finally,  our results showed that both ESR and CRP were 
significantly increased in patients who received PPIs compared with those in 
control group. We confirm previous results that showed the use of PPIs 




 The findings of the present study showed that the use of PPIs was 
associated significantly with increased inflammatory biomarkers. We think 
that health settings should pay much attention to the role of pharmacists and 
pharmacy doctors to increase the awareness about the use of PPIs.  
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